New hope for rare cancers: drug combo trial launches
NCT ID NCT04449549
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 29 times
Summary
This study tests two drugs, nilotinib and paclitaxel, together in people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the combination can shrink or stop tumor growth. About 82 adults with specific rare cancers like certain ovarian cancers, anal cancer, or Ewing sarcoma will take part. Participants take nilotinib by mouth twice daily and receive paclitaxel through a vein once a week for three weeks of each 28-day cycle.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.